Sind SARS-CoV-2-reaktive T‑Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?

The pandemic attributable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly changed life in most countries of the world for more than 1.5 years now. The spread could be more or less well-controlled and fatalities could partly be avoided by obligatory wearing of masks, conta...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, J., Westhoff, T., Baraliakos, X., Babel, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Forschung Aktuell
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445008/
https://www.ncbi.nlm.nih.gov/pubmed/34529110
http://dx.doi.org/10.1007/s00393-021-01083-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445008/
https://www.ncbi.nlm.nih.gov/pubmed/34529110
http://dx.doi.org/10.1007/s00393-021-01083-3

Ejemplares similares